静脉注射免疫球蛋白治疗非副肿瘤性自身免疫性视网膜病变
Intravenous Immunoglobulin for Management of Non-paraneoplastic Autoimmune Retinopathy.
作者信息
Fekri Sahba, Soheilian Masoud, Rahimi-Ardabili Babak
机构信息
Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Ophthalmology, Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
出版信息
J Ophthalmic Vis Res. 2020 Apr 6;15(2):246-251. doi: 10.18502/jovr.v15i2.6743. eCollection 2020 Apr-Jun.
PURPOSE
To report a case of non-paraneoplastic autoimmune retinopathy (npAIR) treated with intravenous immunoglobulin (IVIG).
CASE REPORT
A 12-year-old boy presented with progressive visual field loss, nyctalopia, and flashing for three months. He had suffered from common cold two weeks before the onset of these symptoms. On the basis of clinical history and paraclinical findings, he was diagnosed with npAIR, and IVIG without immunosuppressive therapy was started. During the one-year follow-up period after the first course of IVIG, flashing disappeared completely. Visual acuity remained 10/10, but nyctalopia did not improve. Multimodal imaging showed no disease progression.
CONCLUSION
Although established retinal degenerative changes seem irreversible in npAIR, IVIG may be a suitable choice to control the disease progression.
目的
报告1例接受静脉注射免疫球蛋白（IVIG）治疗的非副肿瘤性自身免疫性视网膜病变（npAIR）病例。
病例报告
一名12岁男孩出现进行性视野缺损、夜盲和闪光感3个月。在这些症状出现前两周他患过感冒。根据临床病史和辅助检查结果，他被诊断为npAIR，并开始接受IVIG治疗且未进行免疫抑制治疗。在首个IVIG疗程后的一年随访期内，闪光感完全消失。视力保持在10/10，但夜盲没有改善。多模式成像显示疾病无进展。
结论
尽管在npAIR中已确立的视网膜退行性改变似乎不可逆转，但IVIG可能是控制疾病进展的合适选择。
Zotero 插件